Fundamentaldaten Incyte Pharmaceuticals - 500 Beiträge pro Seite

[Roohme]

Ich möchte hier zu Sammeln von Fundamentaldaten zu Incyte anregen. Dabei spielt es m.E. keine Rolle, ob die Artikel schon ein paar Wochen alt sind. Also, wer etwas hat, soll es posten.

Ich mache mal den Anfang.

Dienstag, 09.05.2000, 16:47

Incyte Genomics und nationales Gesundheitsinstitut
kooperieren

PAOLO ALTO (dpa-AFX) - Incyte Genomics wird bei der
Sequenzierung der menschlichen Erbanlagen mit den National
Institutes of Health (NIH) zusammenarbeiten. Wie das
Unternehmen am Dienstag mitteilte, werde man die
Forschungsergebnisse öffentlich zugänglich machen. Das Projekt
werde im Rahmen der "Mammalian Gene Collection" (MGC) laufen.

sDie MGC solle einen umfassenden Genkatalog von Mäuse- und Menschengenen erstellen und für die Öffentlichkeit
abrufbar machen. Gegenwärtig sei dies nur für 6000 der 100.000 Gensequenzen der Fall. Von der Zusammenarbeit
verspreche man sich eine Beschleunigung der Forschung in diesem Bereich und langfristig ein besseres Verständnis der
Krankheitsursachen auf molekularer Ebene./jk/kg

[Roohme]

Hatten wir schon. Nur zur Vollständigkeit:

Tuesday June 6, 8:32 am Eastern Time

Company Press Release

SOURCE: Incyte Genomics, Inc.

Incyte Genomics and Roy Castle International Centre Partner to Advance
Research on Lung Cancer Genetics

PALO ALTO, Calif., June 6 /PRNewswire/ -- Incyte Genomics, Inc. (Nasdaq: INCY - news), the leading genomic information company, and the Roy Castle
International Centre for Lung Cancer Research (RCIC) in Liverpool, England, announced today a partnership to study the role of genes in the prevention, diagnosis, and
treatment of lung cancer.

The new agreement is part of Incyte`s ongoing strategy to expand partnerships with the academic research community in addition to pharmaceutical and biotechnology
companies. Intellectual property resulting from this collaboration will be jointly owned by RCIC and Incyte and available for licensing through Incyte.

``Partnerships like these are the first steps in creating a global network of scientists investigating the molecular basis of disease with a common set of gene data and
analysis tools, much like the way chemists use the periodic table,`` said Roy A. Whitfield, Chief Executive Officer of Incyte. ``Our database subscribers will benefit from
the ability to access the increased level and depth of genomic data generated from our collaborations with premier academic research institutions like the Roy Castle
International Centre.``

Incyte will provide RCIC scientists with access to the world`s most extensive set of information on the human genome, including LifeSeq® Gold, Incyte`s flagship gene
sequence database. In turn, scientists at the Centre will work closely with Incyte in designing a collaborative study using data and material derived from the center`s high
quality lung cancer samples. Incyte will analyze both gene and protein expression in the samples and incorporate it into the LifeExpress(TM) gene expression database,
which is a powerful platform for examining how gene function influences the progression and treatment of complex diseases like cancer.

``We are very excited about being invited into Incyte`s growing network of partnerships with the global scientific community,`` said Professor John Field, Director of
Research at the RCIC. ``Undoubtedly, it will move us closer to a cure for lung cancer. We hope the findings generated from our joint efforts will help scientists design
new ways to detect tumors in earlier stages and lead us to more effective ways of treating the disease.``

Lung cancer affects millions of people worldwide, including many who do not use tobacco. As the only center of its kind, the RCIC is named after English entertainer
Roy Castle, a non-smoker who died of lung cancer. In conjunction with The Liverpool University, the RCIC is currently studying various factors associated with an
increased risk of lung cancer including lifestyle, genetics and environment. RCIC`s collaboration with Incyte will focus on studying how genetic damage, or damage to
the way that particular genes function, leads to lung cancer.

Genetic damage in the lungs, for example, can be caused by exposure to particular chemicals in tobacco smoke. The damaged genes may produce inappropriate
amounts of protein or even a defective protein, which damages a healthy cell. In order to diagnose lung cancer at the earliest possible stage and develop new treatments,
it is necessary to identify which of the genes in the human genome function abnormally as a result of genetic damage. In the future, these genes and their resulting
proteins, will serve as valuable diagnostic and therapeutic targets.

``This partnership represents a unique attempt to define human lung cancer in a completely new way, by comparing how each gene in the genome functions in a tumor
versus a healthy lung from the same patient,`` said Randy Scott, Ph.D., President and Chief Scientific Officer of Incyte. ``We are pleased to support the Roy Castle
International Centre`s efforts with this type of analysis, which is perfect for examining the genetic origins of complex diseases like cancer. Rather than studying genes
one by one using traditional methods, scientists can use our technologies to evaluate thousands of genes simultaneously.``

Last fall, Incyte announced a similar research alliance with the Huntsman Cancer Institute at the University of Utah to study the genetics of colon cancer. In the last
year, Incyte has broadened its partnerships with the academic community through collaborations with the University of Cambridge, University of Washington, and the
National Institutes of Health.

The Roy Castle Lung Cancer Foundation is the charity that operationally finances the work of the Roy Castle International Centre for Lung Cancer Research. For more
information on the research in the center, visit the web site at www.roycastle.org.

Incyte Pharmaceuticals, Inc. (doing business as Incyte Genomics, Inc.) is the leading provider of an integrated platform of genomic technologies designed to aid in the
understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software,
microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers
with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and
correlation of gene sequence variation to disease. For more information, visit Incyte`s web site at www.incyte.com.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to Incyte`s ability to expand partnerships with
academic, pharmaceutical and biotechnology companies, are forward-looking statements within the meaning of the ``safe harbor`` provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the
extent of utilization of genomic information by these entities; risks relating to the development of new products and their use by potential collaborators; the ability to
implement technological improvements; the impact of alternative technological advances and competition; the ability of the Company to obtain and retain customers; and
other risks detailed from time to time in Incyte`s SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2000. Incyte disclaims any
intent or obligation to update these forward-looking statements.

[Roohme]

FOOL`S DEN
A Foolish Checklist for Biotech Investing
By Zeke Ashton (TMF Centaur)
June 13, 2000

Article Synopsis: Many investors see the potential that biotechnology offers but are mystified about where to begin. Investors new to biotech investing can use our Foolish checklist to assign a given company to one of three tiers and figure out whether it`s got the stuff to succeed.


Biotechnology investing has been hot over the last year, the most recent Nasdaq plunge notwithstanding. The intense media scrutiny of the genomics revolution and the strong momentum in the sector means that many individual investors have hitched a ride on the biotech bandwagon. While biotechnology`s amazing potential to revolutionize healthcare justifies a lot of the enthusiasm for the sector, investors need to be aware of its risks as well as its possible rewards.

The downside for companies that don`t get FDA approval or aren`t able to achieve their desired statistical endpoints in clinical trials can be severe. The stocks of such companies typically get whacked by investors when the bad news is released. Alkermes (Nasdaq: ALKS) , which suffered a setback with the recent decision by partner Johnson & Johnson (NYSE: JNJ) to discontinue the development of a sustained-release version of J&J`s Procrit, is the most recent example of this piñata effect. Biotech also involves some complicated technology, and much of it extends well beyond the knowledge of the average Fool. Even professional biotech investors have a hard time grasping the science at the core of many biotech products.

So how can your everyday Joe Fool hope to make any headway in the exciting but mystifying world of biotechnology? Let`s see if we can reduce biotech investing to a reasonably simple formula.

Divide and Conquer
First of all, there`s a wide variety of biotechnology companies out there. Some of them are already making rules in the industry and are raking in huge profits from products already on the market. Others have promising research pipelines and are close to breaking through with a new blockbuster drug that will propel them to profitability. Still others have promising technology but are still in the early stages of development. To simplify matters, I suggest that investors divide biotech companies into three groups: a top tier, which represents the established, large-cap biotech companies; a second tier, which includes companies that are close to being profitable; and a third tier, which includes everybody else.

The top tier consists of companies that already have one or more successful products on the market and enjoy minimum annual revenues of $500 million. Here are some of the companies in this tier: Amgen (Nasdaq: AMGN) , Biogen (Nasdaq: BGEN) , Chiron (Nasdaq: CHIR) , Genentech (NYSE: DNA) , Genzyme (Nasdaq: GENZ) , Immunex (Nasdaq: IMNX) , Medimmune (Nasdaq: MEDI) , Biochem Pharma (Nasdaq: BCHE) , and PE Biosystems (NYSE: PEB) .

My advice to investors who want some biotech exposure but don`t want to go back to school to get a biology degree? Start with this top tier. The companies on this list are all either profitable or will likely be profitable within the next year or two. In addition, the revenues that these companies are pulling in allow them to invest more money in research & development programs. While still risky, these companies will likely hold up better than others in the event of a disappointment in their research pipeline. They will probably also be more resilient in a nasty market sell off than second- and third-tier companies would. Finally, these companies lend themselves to traditional financial analysis much more readily than the other biotechs.

Now let`s move on to the second group. There are many fine companies in this group that have either drugs on the market with growing sales or drugs that are potential big sellers in late-stage clinical trials. Also included here are the early movers in the much-publicized race to provide genetic information and gene-based drug discovery services. Let`s call this group tier two. Some of the companies in this tier will go on to become huge winners, while others will never quite break through. All of them involve significant risk.

Some of the companies in tier two are: Gilead Sciences (Nasdaq: GILD) , IDEC Pharmaceuticals (Nasdaq: IDPH) , ICOS (Nasdaq: ICOS) , IDEXX Labs (Nasdaq: IDXX) , Celera Genomics (NYSE: CRA) , Millennium Pharmaceuticals (Nasdaq: MLNM) , Incyte Pharmaceuticals (Nasdaq: INCY) , Human Genome Sciences (Nasdaq: HGSI) , and Affymetrix (Nasdaq: AFFX) .

Beyond the second tier, there are all those companies still looking to get their first drug to market or who are struggling to gain acceptance for their technology platforms. We`ll call these the third tier companies. The companies in this group pose even higher risk than the companies in the second tier. Of course, the opportunity for huge percentage returns is also there, since many of these companies haven`t been discovered by individual investors and are still off the radar screen of most institutions. Professional biotech investors and those with specialized knowledge have an edge with such companies, but an industrious Fool can still find a gold nugget in these waters.

If you find yourself captivated by a biotech company but don`t know how to proceed, use the checklist below to help you in your analysis. It will help you in assigning your prospective investment to one of our three categories.

The Fool`s Biotech Checklist
Biotech companies worthy of investment should have the following:

Successful products on the market
A deep product pipeline with late-stage candidates
Drugs and candidates that target large or underserved markets
Partnerships and marketing agreements with blue-chip drug manufacturers
Research & development spending
Enough cash to fund operations for two years
Experienced management
Favorable Foolish financial analysis
In my next Research article, which will appear on Thursday, I`ll take you through a real-world example to demonstrate the use of this checklist. See you then!

[Roohme]

Thursday June 15, 6:41 pm Eastern Time
worldlyinvestor.com Sector of the Day
Genomics Peace Treaty Won`t Appease Investors
By Nadine Wong, Biotech Stocks Columnist

Talks between federally and privately funded researchers doesn`t necessarliy mean profits for biotechs.



It appears a truce is emerging in the battle over who gets credit for mapping the human genome.

In one corner we have we have the federally funded Human Genome Project. And in the opposing corner we have the challenger, privately funded stock-market darling Celera (NYSE:CRA - news).

The race for the crown was looking like a spirited rivalry until today, when we received word that the two parties are in talks to collaborate on publishing their findings together as early as the fall.

Such an agreement would defuse the tension that has built up between the two parties. But it wouldn`t do much for Celera`s prospects of making money in the genome business -- a massive challenge that the company must meet soon if it`s going to hold together.

Genomic Explosion
Celera deserves credit for being aggressive, and it may well be the industry`s leader for some time. But I prefer other genomic companies, such as Incyte (Nasdaq:INCY - news), Human Genome Sciences (Nasdaq:HGSI - news), Millennium (Nasdaq:MLNM - news) and Myriad Genetics (Nasdaq:MYGN - news) for the long haul. They`ve made more progress, are more established and look like they will deliver on their promises to the market.

If you were savvy about genomics back in 1997, when the field was in its embryonic stage, you could count all the publicly traded companies on both hands. An investment in almost any one of them would have paid off handsomely.

Today, you need your toes and then some to even come close to the number of companies that have popped up to help decipher the complicated human genetic code. The choices of which to invest in are far more complex and confusing. So what are you to do?

The first step is to separate the hype from the reality by determining how genomics companies can justify their valuations. I have a few favorites, companies that I believe can support continued growth in this emerging field and that will perform well over the course of time. Their share prices have fallen from peaks earlier this year, but they have regained a portion of their losses.

Insight on Incyte
For mining the human genome, I`ve always been an advocate of Incyte. This company was the original genomic company, which came up with the business model of using computers and building databases for sale.

Then Celera came onstage and knocked Incyte out of the spotlight. Celera can offer genetic databases that aren`t limited to human genes, and that includes other species for comparison, such as the mouse and fruit fly. In my opinion, however, Incyte is just as competitive and as solid a company.


To figure out what the genes do and the role they perform, companies such as Millennium, Human Genome Sciences and Gene Logic (Nasdaq:GLGC - news) are good bets. Millennium bought Leukosite, which will probably help provide a revenue stream when the company brings a cancer drug to market.

Human Genome Sciences has a management team that can realize the company`s vision. Lastly, Gene Logic hopes to sign up more customers to its database to validate the company`s technology. Gene Logic has a database of diseased tissues that should be a valuable tool for scientists to help compare and understand what genes play a role in the development of disease. This could potentially speed up progress in identifying new drug targets and enhance drug development.

Then there are the manufacturers of DNA chips that are more than likely to have an immediate earnings payoff. I`m a believer in Affymetrix (Nasdaq:AFFX - news), which is the originator and leader in its field. Affymetrix should be churning out earnings probably within a year.

Don`t Forget Your Protein
With all the DNA information coming out the next big push will be in the area of proteomics -- the study of proteins and how they interact. This is going to be a hot field because genes make proteins that can be made into drugs or be a target for a drug. Myriad Genetics (Nasdaq:MYGN - news) is utilizing its ProNet technology to help elucidate disease pathways that should help companies that subscribe to this database to identify new protein targets.

With the mapping of the human genome, scientists now have the ability to read the DNA that makes up the genetic code. This opens the gate to an arena that promises to revolutionize medicine and allows investors to participate in this growth. The number of genomic companies has expanded, but I prefer the more established names rather than the newcomers. The more experienced companies, I feel, will pass judgment in the eyes of the Street.

Nadine Wong is editor and publisher of <a href=``http://www.biotechnav.com/``>the BioTech Navigator Newsletter,</a> the leading biotech investment newsletter in the nation. Her weekly column looks at the hottest stocks in the biotech sector. Wong currently has a position in Gene Logic. Positions may change at any time.